Preclinical data supports arenaviral therapeutic vaccine for hepatitis B
Drug Discovery World
OCTOBER 27, 2023
HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing.
Let's personalize your content